Seres Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
SER-155 showed an 80% immunosuppressive-free response rate in moderate to severe irEC, with rapid and durable symptom improvement and favorable safety. Biomarker and pharmacology data support its mechanism, and a phase II trial is planned to further evaluate its potential.
-
The meeting covered director elections, auditor ratification, executive compensation, and an amendment to the incentive award plan, with all proposals approved. No questions were submitted by stockholders, and final voting results will be published in a Form 8-K.
-
The presentation highlighted advances in microbiome-based therapeutics, including a phase II-ready asset with strong efficacy data and the integration of generative AI into drug development. Near-term milestones include key clinical readouts and strategic partnerships, with a focus on high-need patient populations.
-
Management transitions and a focused strategy are driving live biotherapeutic programs in inflammatory and immune diseases. Key clinical milestones include an upcoming SER-155 irEC data readout and ongoing development of SER-603 for IBD. Cash runway extends through Q3 2026.
Fiscal Year 2025
-
The company is advancing SER-155 for allo-HSCT patients, showing strong phase Ib efficacy and safety, with FDA-aligned phase II plans and significant commercial potential. Expansion into broader indications and new programs like SER-603 for IBD are underway, supported by ongoing partnerships and funding through Q2 next year.
-
SER-155 advanced toward phase two for bloodstream infection prevention, with strong phase 1B results and FDA alignment. Q3 saw a return to net income, cost reductions, and a CARB-X grant, while further progress depends on securing additional funding.
-
SER-155 advanced to Phase 2 readiness with strong prior results and global study plans. Q2 net loss narrowed, cash runway extends into Q1 2026, and active efforts are underway to secure capital through partnerships or mergers amid a challenging biotech environment.
-
Q1 2025 saw a return to profitability driven by a $50M Nestlé payment, reduced expenses, and a strong cash position. SER-155 advanced toward phase II, with study initiation dependent on partnership, and received positive regulatory and clinical feedback.
-
SER-155 demonstrated strong efficacy and safety in preventing infections in allo-HSCT patients, earning Breakthrough Therapy Designation and positioning for a pivotal study. The company is focused on advancing SER-155, supported by a streamlined structure, extended cash runway, and strategic partnerships.
Fiscal Year 2024
-
SER-155 showed a 77% reduction in bloodstream infections in allo-HSCT patients, with strong safety and biomarker data. Financials improved year-over-year, and the company is preparing for a Phase II study while seeking partners and expanding indications.
-
The company is advancing microbiome therapies for serious infections, highlighted by SER-155, which showed a 77% reduction in bloodstream infections in allo-HSCT patients. After selling VOWST rights to Nestlé, it has a strong cash position and is preparing for pivotal trials and potential FDA designations.
-
Q3 2024 saw strong SER-155 Phase I-B results and the VOWST sale, boosting capital and enabling debt retirement. SER-155 reduced BSIs by 77% in Allo-HSCT patients, and the company is pursuing FDA designations and partnerships to expand its pipeline.
-
Recent clinical data show SER-155 significantly reduced bloodstream infections and antibiotic use in allo-HSCT patients, supporting further development and FDA engagement. The company is also advancing SER-147 for chronic liver disease and leveraging lessons from VOWST to optimize its pipeline.
-
SER-155 showed significant reductions in bacterial bloodstream infections, antibiotic exposure, and febrile neutropenia in allo-HSCT patients, with a favorable safety profile and robust GI engraftment. Plans are underway to advance development and seek regulatory engagement.
-
Q2 2024 saw a net loss of $32.9M, with reduced R&D and G&A expenses and a strong cash position. SER-155 phase Ib Cohort 2 data is expected soon, potentially enabling a global pivotal study, while the VOWST asset sale to Nestlé will extend the cash runway and streamline operations.
-
VOWST assets and rights will be sold to Nestlé for $155 million upfront, milestone payments, and equity investment, with additional future payments possible. Proceeds will retire debt and fund SER-155 and pipeline development, with a cash runway into Q4 2025.